However, some recent studies are in line with our data: ESR1neg breast cancers (which are mostly TP53 mutant) were found to be more sensitive to neoadjuvant chemotherapy [7] and, in a pilot study, TP53 staining was associated with favorable responses to preoperative anthracyclins [42]. The gene discussed is TP53; the disease is breast cancer.